PriceTargets.com logo

Apexigen - APGN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.39 As of 09/1/2023 01:00 AM ET
+0 (0.00%)
Get New Apexigen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APGN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Apexigen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.39.

This chart shows the closing price for APGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Apexigen. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/10/2023Brookline Capital ManagementDowngradeBuy ➝ HoldLow
1/24/2023Roth CapitalReiterated RatingBuy$15.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$8.00Low
12/12/2022Brookline Capital ManagementReiterated RatingBuyLow
10/17/2022Roth CapitalInitiated CoverageBuyLow
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Apexigen logo
Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $0.39
Low: $0.39
High: $0.39

50 Day Range

MA: $0.39
Low: $0.36
High: $0.44

52 Week Range

Now: $0.39
Low: $0.33
High: $8.28

Volume

N/A

Average Volume

967,731 shs

Market Capitalization

$9.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Apexigen?

The following sell-side analysts have issued reports on Apexigen in the last year:
View the latest analyst ratings for APGN.

What is the current price target for Apexigen?

0 Wall Street analysts have set twelve-month price targets for Apexigen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Apexigen in the next year.
View the latest price targets for APGN.

What is the current consensus analyst rating for Apexigen?

Apexigen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for APGN.

What other companies compete with Apexigen?

Other companies that are similar to Apexigen include Moleculin Biotech, Aeterna Zentaris, Akari Therapeutics, Alterity Therapeutics and Elevai Labs. Learn More about companies similar to Apexigen.

How do I contact Apexigen's investor relations team?

Apexigen's physical mailing address is 280 PARK AVENUE SUITE 43W, NEW YORK NY, 10017. The company's listed phone number is 650-931-6236. The official website for Apexigen is www.apexigen.com. Learn More about contacing Apexigen investor relations.